Organization
Agios Pharmaceuticals
14 clinical trials
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-label Extension PeriodStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Subjects With Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2023-12-19
Clinical trial
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized, Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic SyndromesStatus: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and NephropathyStatus: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 StudiesStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent ThalassemiaStatus: Active (not recruiting), Estimated PCD: 2020-08-20
Clinical trial
A Rollover Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat StudyStatus: , Estimated PCD: 2029-08-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused, Followed by a 5-Year Open-label Extension PeriodStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)Status: Active (not recruiting), Estimated PCD: 2023-11-13
Clinical trial
A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase DeficiencyStatus: Active (not recruiting), Estimated PCD: 2017-05-08
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AG-181 in Healthy ParticipantsStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1, Open-label, Single-dose, Pharmacokinetic Study of Mitapivat in Subjects With Moderate Hepatic Impairment Compared to Matched Healthy Control Subjects With Normal Hepatic FunctionStatus: Completed, Estimated PCD: 2023-07-21